Plasma pTau181 is associated with subjective cognitive concerns but not objective cognitive decline or structural brain integrity measures in midlife
Ashleigh Barrett-Young·Reremoana Theodore·Brigid Ryan·Wickliffe C. Abraham·Antony Ambler·Tim Anderson·Kirsten Cheyne·Elizabeth Goodin·Sean Hogan·Renate Houts·David Ireland·Annchen R. Knodt·Jesse Koka'ua·Tracy R. Melzer·Sandhya Ramrakha·Karen Sugden·Benjamin Williams·P.D. Wilson·Avshalom Caspi·Ahmad R. Hariri·Terrie E. Moffitt·R. Poulton·Erin E. Cawston
Abstract Although plasma pTau181 has been shown to accurately discriminate patients with Alzheimer’s disease from healthy older adults, there are few studies of plasma biomarkers among middle-aged populations. Given the potential utility of plasma AD biomarkers such as pTau181 in screening for disease risk, examining pTau181 in a middle-aged cohort without AD is important for future implementation. The objectives of this study were to characterise plasma pTau181 in a middle-aged birth cohort age